Book a demo

Barrier Tissue Models Patents: Who Leads, Where the Gaps Are 2026

Barrier Tissue Models Patents: Who Leads, Where the Gaps Are 2026
Data to 2026-07-31

Barrier tissue model patents: mapping the assignees, claim density and filing momentum behind blood-brain and epithelial barrier IP

Concentrated but not locked up. the top 5 assignees hold 21.3% of all 2,609 records in scope and the top 10 hold 32.2% — a leader plus a long tail of single- and few-filing entrants. Annual filings peaked at 174 records in 2017 and have settled into a lower but still-active band since; the 2021-to-2024 window shows a 7% rise (88 to 94 records), and figures from 2025 onward are undercounted because publication typically lags filing by around 18 months.

Filing trend: a 2017 peak followed by a durable plateau
Complete Incomplete
Filing trend: a 2017 peak followed by a durable plateau05010015020017420172018201920202021202220232024202552026Most recent year is partial — publication lag means later filings are not yet visible.
2,609
Published Records
21%
Top-5 Share of All Records
+7%
Filing Growth 2021→2024
US
Leading Jurisdiction
Top filers · share of all 2,609 records
  1. 1UNIVERSITY OF ZURICH5.3%
  2. 2BIOGEN INT NEUROSCI4.6%
  3. 3NV NUTRICIA4.4%
  4. 4AC IMMUNE SA3.6%
  5. 5EMULATE INC3.4%
Published by Patsnap Research·

See the full barrier tissue models analysis in Eureka

  • The complete ranking, not just the top five
  • Every IPC branch with its share of the corpus
  • The most-cited records, and where claim space is still thin
Read more about this analysis in Eureka
FAQ

Common questions on barrier tissue model patents

Who holds the most patents on barrier tissue models?+

University of Zurich leads the ranked assignees with 137 records, ahead of a group of academic, clinical and specialist filers including Biogen International Neuroscience, Nutricia, AC Immune, and Emulate Inc. in the top five. Together the top five hold 21.3% of all 2,609 records in scope, and the top ten hold 32.2%, which means the field has a visible leader but is far from consolidated. Most of the remaining records are spread across a long tail of single- or few-filing entrants, many of them universities and hospital systems rather than commercial platform companies.

Is the barrier tissue model patent field growing or slowing down?+

Filing peaked at 174 records in 2017 and has settled to a lower plateau since, but the trend is not a decline: 2021 to 2024 filings rose from 88 to 94 records, a 7% increase over that span. Numbers for 2025 and 2026 will look artificially low because patent publication typically lags actual filing by around 18 months, so those most recent years are still being backfilled in any dataset pulled today. Judged on the last complete years, filing activity is holding steady to slightly rising, not shrinking.

What does US20200339956A1 actually claim?+

US20200339956A1, filed by University of Lancashire and published 2020-10-29, claims a barrier structure built from endothelial cells, astrocytes and pericytes within a three-dimensional cell growth material, specified to reach a transepithelial electrical resistance (TEER) value of at least 450 Ω/cm2. It further specifies the structure sits inside a container that separates two chambers on either side of the barrier, and that the cells may be primary, non-immortalised human cells derived from brain tissue. Anyone building a blood-brain barrier model with a comparable cell mix and TEER performance threshold should read this claim closely rather than assume it only covers the general concept of a BBB model.

Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.

Method: Filing trend and technology composition. Derived from a Patsnap search on Barrier Tissue Models covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.